Addex Therapeutics (ADXN) AI Stock Analysis

• Market Cap: $9.83M
• Dividend Yield: N/A
• Average Volume (3M): 16.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: -80.31%
• EPS Growth: -293.92%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 1,822,121
• 10 Day Avg. Volume: 4,441
• 30 Day Avg. Volume: 16,099
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 12.86
• P/FCF Ratio: -0.97
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $8.00 ▼(-11.01% Downside)

Addex Therapeutics' overall stock score reflects significant financial challenges, including persistent losses and cash flow issues. The technical analysis indicates a bearish trend, while the valuation is constrained by a negative P/E ratio. Despite these challenges, the earnings call provided some positive developments in strategic partnerships and R&D progress, offering potential future upside.

Positive Factors

Strategic Partnerships

Strategic partnerships with potential milestone payments and royalties provide a strong revenue stream, enhancing long-term financial stability and supporting R&D efforts.

Regained Program Rights

Regaining program rights allows Addex to explore new therapeutic indications, potentially expanding its pipeline and increasing future revenue opportunities.

Cash Runway

A cash runway through mid-2026 ensures operational stability, allowing Addex to focus on strategic initiatives and R&D without immediate financial pressure.

Negative Factors

Negative Cash Flow

Ongoing negative cash flow highlights operational inefficiencies and reliance on external financing, which could limit long-term growth and strategic flexibility.

Declining Revenue

A declining revenue trend and negative margins suggest challenges in market penetration and cost management, impacting long-term profitability.

Limited Cash for Unpartnered Programs

Insufficient funds for unpartnered programs may hinder the development of new therapies, limiting future growth and diversification of the product pipeline.

Addex Therapeutics Business Overview & Revenue Model

Company Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

How the Company Makes Money

Addex Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model includes potential milestone payments from strategic partnerships with larger pharmaceutical companies that may license its drug candidates for further development and marketing. Additionally, Addex may receive royalties on sales of products that are successfully commercialized as a result of these partnerships. The company also engages in research collaborations and grants that can provide funding for its ongoing development programs, contributing to its financial sustainability.

Addex Therapeutics Financial Statement Overview

Summary

Addex Therapeutics faces significant financial challenges, with negative profitability and cash flow issues. Despite a strong equity position and low leverage, the company struggles with persistent losses and cash flow difficulties, typical of early-stage biotech firms.

Income Statement

Addex Therapeutics has faced significant challenges in its income statement, with consistently negative gross profit margins and net income over the years. The company also shows a declining revenue trend, with revenue decreasing from 2020 to 2024. The gross profit margin and net profit margin are negative, indicating that the company is struggling to manage costs relative to its revenue, which is common in early-stage biotechnology companies.

Balance Sheet

The balance sheet reflects a relatively strong equity position with a high equity ratio. The debt-to-equity ratio is low, indicating limited leverage, which is a positive sign of financial stability. However, the company has experienced a decrease in total assets over the years, and stockholders' equity has fluctuated, reflecting volatility in its financial position.

Cash Flow

Addex Therapeutics has experienced persistent negative free cash flow, indicating challenges in generating cash from operations. Although there was a decrease in negative operating cash flow in 2024, the company continues to rely on external financing. The free cash flow to net income ratio is unfavorable, highlighting ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	91.72K	404.10K	1.61M	1.42M	2.92M	3.61M
Gross Profit	-142.73K	404.10K	1.61M	1.42M	2.92M	3.61M
EBITDA	-6.06M	-4.65M	-2.19M	-10.45M	-14.94M	-12.41M
Net Income	-6.05M	7.06M	-10.56M	-20.80M	-15.35M	-12.86M
Balance Sheet
Total Assets	8.51M	10.68M	4.64M	8.28M	22.54M	20.18M
Cash, Cash Equivalents and Short-Term Investments	2.30M	3.35M	3.87M	6.96M	20.50M	18.76M
Total Debt	38.39K	41.99K	344.34K	373.13K	482.01K	567.40K
Total Liabilities	1.29M	1.00M	3.50M	3.37M	5.61M	5.57M
Stockholders Equity	7.21M	9.68M	1.15M	4.91M	16.93M	14.61M
Cash Flow
Free Cash Flow	-1.44M	-5.37M	-8.00M	-16.44M	-14.74M	-12.24M
Operating Cash Flow	-1.44M	-5.37M	-7.99M	-16.44M	-14.71M	-12.18M
Investing Cash Flow	-759.10K	4.65M	-6.84K	2.97K	-30.31K	-59.41K
Financing Cash Flow	744.97K	104.92K	5.26M	3.10M	16.40M	46.40K

Addex Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXN, the sentiment is Positive. The current price of 8.99 is above the 20-day moving average (MA) of 8.34, above the 50-day MA of 8.85, and above the 200-day MA of 8.36, indicating a bullish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 55.31 is Neutral, neither overbought nor oversold. The STOCH value of 65.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADXN.

Addex Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KPRX	56 Neutral	$8.14M	-0.72	-32.58%	―	-100.00%	-463.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADXN	44 Neutral	$9.83M	―	-61.65%	―	-80.31%	-293.92%
XBIO	43 Neutral	$6.49M	-1.43	-57.43%	―	13.30%	22.70%
HCWB	39 Underperform	$5.38M	―	―	―	-87.93%	65.26%
NCNA	28 Underperform	$16.52M	―	-179.40%	―	―	94.52%

Addex Therapeutics Corporate Events

Addex Therapeutics Earnings Call: Strategic Gains Amid Challenges

The recent earnings call for Addex Therapeutics Ltd (ADR) presented a balanced sentiment, highlighting both significant achievements and notable challenges. The company showcased its progress in strategic partnerships and financial stability, while also addressing decreased income and increased net loss from associated ventures. The call also pointed out the limited cash available for unpartnered programs, painting a comprehensive picture of the company’s current standing.

Addex Therapeutics Reports Significant Loss Amid Financial Challenges

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Switzerland, focusing on developing novel small molecule allosteric modulators for neurological disorders. The company operates in the pharmaceutical industry and is known for its innovative approach to drug discovery and development. In its latest half-year interim report for 2025, Addex Therapeutics reported a significant net loss, highlighting the financial challenges it faces. The company recorded a net loss of CHF 3.3 million for the first half of 2025, compared to a net profit of CHF 9.8 million in the same period of 2024, primarily due to the absence of revenue from contracts with customers and increased operating costs. The report also noted a decrease in cash and cash equivalents, which stood at CHF 2.3 million as of June 30, 2025, down from CHF 3.3 million at the end of 2024. Despite these challenges, Addex Therapeutics continues to focus on its core research and development activities, with operating costs primarily driven by these efforts. The company’s management remains committed to securing additional funding to support its operations and future growth. Looking ahead, Addex Therapeutics aims to continue its strategic focus on developing its portfolio of allosteric modulators, while actively seeking collaborations and partnerships to enhance its financial stability and operational capabilities.